Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Assets Average (2020 - 2025)

Historic Assets Average for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $514.8 million.

  • Tarsus Pharmaceuticals' Assets Average rose 3670.09% to $514.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $514.8 million, marking a year-over-year increase of 3670.09%. This contributed to the annual value of $321.2 million for FY2024, which is 3022.74% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Assets Average stood at $514.8 million for Q3 2025, which was up 3670.09% from $497.9 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Assets Average ranged from a high of $514.8 million in Q3 2025 and a low of $180.2 million during Q1 2022
  • Over the past 5 years, Tarsus Pharmaceuticals' median Assets Average value was $232.2 million (recorded in 2022), while the average stood at $285.7 million.
  • Its Assets Average has fluctuated over the past 5 years, first tumbled by 786.76% in 2023, then skyrocketed by 8146.65% in 2024.
  • Over the past 5 years, Tarsus Pharmaceuticals' Assets Average (Quarter) stood at $184.7 million in 2021, then rose by 25.73% to $232.2 million in 2022, then rose by 14.97% to $266.9 million in 2023, then surged by 41.11% to $376.6 million in 2024, then soared by 36.67% to $514.8 million in 2025.
  • Its Assets Average was $514.8 million in Q3 2025, compared to $497.9 million in Q2 2025 and $438.9 million in Q1 2025.